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Neurodegenerative pathologies represent a challenge for 
modern medicines especially in developed countries where life 
expectancy is higher. Patients suffering from Alzheimer’s and 
Parkinson’s diseases are confronted with the lack of adequate 
therapies that can provide a partial or complete reversal of 
neural death.
1
 In this context, new therapeutical targets or new 
treatment strategies to fight mental dementia have attracted 
much research efforts from both academia and pharmaceutical 
companies in the recent years.
2
 The neurotransmitter glutamate 
plays a pivotal role in the synaptic plasticity since its 
accumulation in the synaptic cleft activates the N-Methyl-D-
Aspartate receptor (NMDAR), a subtype of ionotropic 
glutamate receptors (iGluR).
3
 The NMDAR allows the influx 
of calcium ions (Ca
2+
) to the neuron, thus reestablishing the 
membrane potential after the synapse. However, if there is a 
rapid increase in intracellular Ca
2+
 levels, it can lead to 
neuronal death trough mitochondrial dysfunction, a process 
that has been named excitotoxicity.
4 
These neuronal receptors 
are heteromers formed by the assembly of different 
combinations of three or four NR1, NR2A-NR2D and NR3A-
NR3B subunits which form Ca
2+
 permeable transmembrane 
channels. At the NR1 subunits is where the NMDAR co-
agonist glycine will bind. On the other hand glutamate will 
bind to the NR2 subunits. Besides the need for the 
simultaneous binding of two agonists other unique features of 
NMDAR activation are its voltage-dependence and when 
resting its ion pore is permanently blocked by extracellular 
Mg
2+
.
5 
In fact, the development of biologically active compounds that 
block NMDAR excessive activity and simultaneously maintain 
their physiological role unharmed is incredibly challenging due 
to the complex pharmacology and molecular architecture of 
these receptors. For this reason, blocking NMDARs 
completely with high affinity antagonists has already been 
shown not to be therapeutically useful.  
 
 
 
 
Figure 1. Known N-methyl-D-aspartate receptor antagonists.  
In the last decades, several types of NMDAR antagonists with 
a wide range of action mechanisms have been reported but 
unfortunately only few exhibited proper pharmacokinetics and 
tolerable side effects in human trials.
6
 A successful example is  
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amantadine, a low-affinity NMDA channel blocker, currently 
used to mitigate levodopa-induced dyskinesia in Parkinson’s 
disease.
7
  
In 2009, a group of oxazolidines 1 was described as NMDAR 
antagonists by preventing the binding of NMDAR ligands 
through a yet unknown mechanism of action.
8
 Based on this 
information, we decided to test a small library of 
phenylalaninol-derived oxazolopyrrolidones, which contain an 
oxazolidine ring but have a more rigid structure than 
compounds 1. In fact, we discovered a hit compound 2 with an 
IC50 of 62 µM in cultured cerebellar granule neurons (Fig. 1).
9 
Following our first encouraging results in the development of 
novel chemotypes of NMDAR antagonists, we have decided to 
explore if related derivatives have enhanced activity.  
Here, we present our biological activity screening results with 
a series of tryptophanol-derived oxazolopiperidones. These 
compounds can be synthesized through chiral-induced 
cyclocondensation reactions between enantiopure tryptophanol 
and racemic or prochiral δ-oxo-esters in moderate to good 
yields.
10
 Compounds 3-5 were synthesized by 
cyclocondensation reaction of S-tryptophanol and the 
appropriate δ-oxo-esters in yields up to 81% (Scheme 1).
11
  
The NMDA receptor blocking activity of compounds 3a-5a 
and 3b-5b was evaluated by measuring the compounds ability 
to inhibit the intracellular calcium increase, induced by 
NMDA, in in vitro cultures of neurons (Table 1).
12
 In our first 
screening of S-tryptophanol-derived oxazolopiperidones, only 
compounds without any substituent in the piperidine ring, 
compounds 3a and 3b, exhibited some activity. Compounds 
4a-5a and 4b-5b were inactive (IC50 > 450 µM) pointing out 
the receptor intolerance for methylene-ester and ethyl chains at 
C-7 and C-8, respectively. 
 
 
 
 
 
Scheme 1. Synthesis of S-tryptophanol-derived oxazolopiperidones. 
Reagents and conditions: 1.1eq of δ-oxo-esters, toluene, 16h Δ, inert 
atmosphere and Dean-Stark apparatus. 
 
Table 1. NMDAR antagonist activity of compounds 3a-5a 
and 3b-5b. 
 aResults are the mean of three independent experiments. 
Bearing in mind the importance of the absolute 
stereochemistry of biologically active compounds, we have 
also prepared a series of R-tryptophanol-derived 
oxazolopiperidones (Scheme 2).  
 
 
 
 
 
Scheme 2. Synthesis of R-tryptophanol-derived oxazolopiperidones. 
Reagents and conditions: 1,1eq. of δ-oxo-esters, toluene, 16h Δ, inert 
atmosphere and Dean-Stark apparatus. 
 
This new series of enantiopure derivatives were also screened 
for NMDAR antagonistic activity and results are summarized 
in Table 2. As observed for the S-tryptophanol derivatives the 
introduction of an ethyl group (7a-7b) or a CH2CO2Me chain 
(8a-8b) in the piperidine ring leads to complete loss of activity. 
Very interestingly, there is a large preference of the NMDA 
receptor for the derivatives containing an unsubstituted 
piperidine ring (compounds 3a, 3b and 6a). The R-
tryptophanol-derived oxazolopiperidone 6a
13
 showed the 
highest potency as a NMDAR antagonist (IC50 of 63.4 µM, see 
Table 2 and Fig. 2) and was 1.5 fold more active than 
amantadine (IC50 = 92 µM), a known NMDAR antagonist. The 
diastereoisomers 3b and 3a, exhibited IC50’s of 305 µM and 
429 µM, being approximately 5 fold and 7 fold less potent as 
NMDAR antagonists than compound 6a. Together, these 
results suggest that an absolute stereochemistry of R at position 
C-3 and S at position C-8a is an important requisite for 
antagonistic activity in this class of compounds. 
 
Table 2. NMDA antagonistic activity of compounds 6a-8a 
and 6b-8b.  
 aResults are the mean of three independent experiments. 
 
Finally, we decided to synthesize derivatives of compound 6a 
to better understand the structural requisites for NMDA 
receptor antagonistic activity. Two compounds with the 
nitrogen atom of the indole moiety protected were synthesized 
(Scheme 3). Compound 9, bearing a tosyl group at the indole 
nitrogen, was synthesized using a phase-transfer reaction.14 
Compound 10, bearing a methyl group at the indole nitrogen, 
was obtained using sodium hydride and iodomethane.
15
 
 
Compound 
yield 
R1 R2 
NMDA (100 µM) 
IC50 (µM)
 a 
6a (11%) H H 63.4±9.0 
6b (49%) H H >450 
7a (12%) Ethyl H >450 
7b (58%) Ethyl H >450 
8a (13%) H CH2CO2Me >450 
8b (57%) H CH2CO2Me >450 
Amantadine — — 92.0±29.1 Compound  R1 R2 
NMDA (100 µM)  
IC50 (µM)
 a 
3a  H H 429.2±142.4 
3b  H H 305.1±37.0 
4a  Ethyl H >450 
4b  Ethyl H >450 
5a  H CH2CO2Me >450 
5b  H CH2CO2Me >450 
Amantadine — — 92.0±29.1 
  
 
 
Scheme 3. Synthesis of compounds 9 and 10. Reagents and conditions: i): 
TsCl, CH2Cl2, NaOH (aq., 30% w/v), TBAI (cat.), 0ºC, 16h. ii): NaH, MeI, 
DMF, 0ºC. 
 
 
 
 
Scheme 4. Synthesis of compound 11. Reagents and conditions: 1,1eq. 
methyl 4-oxobutanoate, toluene, 16h, Δ, inert atmosphere and Dean-Stark 
apparatus. 
 
In order to explore the piperidone ring contraction effect on 
NMDAR antagonism activity we synthesized compound 11 
through a cyclocondensation reaction of R-tryptophanol and 
methyl 4-oxobutanoate (Scheme 4).
16 
This last set of 
structurally related analogs of compound 6a was evaluated for 
NMDAR antagonism and results are depicted at Table 3. The 
introduction of tosyl or methyl substituents at the NH-indole 
position resulted in complete inactivity of compounds 9 and 
10. This observation suggests that there might be a need for a 
polarized N-H bond for the establishment of receptor 
interactions. Compound 11, bearing a pyrrolidone ring, despite 
maintaining the absolute stereoutcome of compound 6a is 5 
fold less potent (IC50 = 341.2 µM). 
 
 
Table 3. NMDA antagonistic activity of compounds 9-11.  
 
 
 
 
 
 
aResults are a mean of three independent experiments. 
 
In conclusion, as far as our knowledge goes, herein we have 
identified for the first time the tryptophanol-derived 
oxazolopiperidone lactam scaffold for the development of 
novel NMDA receptor antagonists. The compounds are easily 
synthesized from enantiopure tryptophanol and racemic δ-oxo-
esters in only one synthetic step and good yields. In particular, 
we discovered that tryptophanol-derived oxazolopiperidone 
lactam 6a is 1.5 fold more active than clinically approved 
NMDA antagonist amantadine. Further studies are being 
conducted to optimize this compound as NMDA receptor 
antagonist in order to develop new oxazolo-piperidone leads 
with potential activity in neurodegenerative diseases. 
 
Figure 2. Inhibitory effect of compounds 3b, 6a, 11, and amantadine on 
NMDA-induced intracellular calcium increase in cultured cerebellar 
granule neurons.  
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